Recent news highlights Microbot Medical's Q1 and Q2 2026 financial results showing losses and revenue below estimates, alongside commercial progress including the full U.S. launch of the LIBERTY system and manufacturing expansion.

• Microbot Medical reported a net loss in Q2 2026 and revenue growth with new customers compared to Q1 2026, indicating early commercial traction [N1].
• The company reported a net loss in Q1 2026 and revenue below estimates, continuing to incur operating losses [N2].
• Microbot began the full U.S. launch of the LIBERTY Endovascular Robotic Surgical System in April 2026 [N1].
• The company entered into a manufacturing agreement with Sanmina Corporation to expand capacity and support cost reduction strategies [S2].
• Analyst coverage includes buy recommendations from HC Wainwright & Co. and Roth Capital in late 2025 and early 2026 [N1].

Microbot Medical has made progress transitioning from R&D to commercialization, including FDA clearance and a full U.S. launch of the LIBERTY system. The company has secured manufacturing capacity through agreements with third parties like Sanmina Corporation, supporting potential scale-up and cost reduction. Recent quarters showed revenue growth and new customer acquisition, indicating initial market traction. The company's patents and regulatory clearances provide a foundation for market entry in the robotic endovascular surgery space. Analyst coverage with buy recommendations in late 2025 and early 2026 reflects positive market interest. If Microbot can successfully expand manufacturing, gain broader clinical acceptance, and secure reimbursement, it may build a sustainable commercial business.

Microbot Medical has a limited operating history as a commercial-stage company and has not yet demonstrated the ability to manufacture at commercial scale or conduct effective sales and marketing. The company has incurred significant operating losses and continues to do so, with no assurance of achieving or sustaining profitability. Market acceptance of the LIBERTY system depends on demonstrating safety, efficacy, cost-effectiveness, and gaining acceptance by medical professionals and payors, which is uncertain. Manufacturing risks include reliance on third parties and potential delays or cost issues. The company faces risks from regulatory approvals, reimbursement challenges, competition, geopolitical factors, and currency fluctuations. Failure to raise additional capital could force delays or reductions in development and commercialization efforts, materially harming the business.

Microbot Medical's moat is centered on its proprietary LIBERTY® Endovascular Robotic Surgical System, supported by FDA clearance and patents expanding its market. The company's focus on robotic endovascular surgery targets a specialized medical device niche with potential clinical advantages. However, the moat is challenged by the company's limited commercial operating history, reliance on third-party manufacturers, and the need to establish broad market acceptance among medical professionals and payors. Intellectual property protection and regulatory approvals provide some barriers to entry, but competition from established medical device companies and emerging technologies remains a risk. The company's ability to scale manufacturing efficiently and secure reimbursement will be critical to sustaining competitive advantages.

• Commercialization Risk: Microbot depends heavily on the successful commercialization of the LIBERTY® system. Delays or failure to establish manufacturing, sales, and marketing capabilities could materially harm the business.
• Financial Risk: The company has incurred significant operating losses and expects to continue incurring losses for the foreseeable future. It relies on equity offerings and grants for funding and has no committed external source of funds.
• Manufacturing Risk: Microbot relies on third-party manufacturers and faces risks related to supply availability, regulatory compliance, and the ability to meet production volumes and quality standards.
• Regulatory and Reimbursement Risk: Obtaining and maintaining regulatory approvals and adequate reimbursement levels are critical. Failure in these areas could limit market acceptance and sales growth.
• Market Acceptance Risk: The LIBERTY system must be broadly accepted by medical professionals and payors as safe, effective, and cost-effective. Competition and perceptions of the product could limit adoption.
• Intellectual Property Risk: The company faces risks related to protecting its patents and proprietary rights, as well as potential infringement claims that could impact operations.
• Geopolitical and Currency Risk: Operations in international markets expose Microbot to risks from geopolitical events, currency fluctuations, and regulatory changes that could adversely affect financial results.

• Microbot Medical Inc. develops and commercializes the LIBERTY® Endovascular Robotic Surgical System, which is its sole product and primary focus.
• The company transitioned from primarily research and development to commercialization in 2025.
• Microbot relies on third-party manufacturers for production, including a Letter of Agreement with Sanmina Corporation to expand manufacturing capacity.
• The company has limited experience in manufacturing and sales and marketing activities necessary for successful commercialization.
• Microbot has not recognized any revenues from product sales through December 31, 2025, but reported revenue growth and new customers in Q2 2026 compared to Q1 2026.
• The company reported net losses in Q1 and Q2 2026, with a net loss of approximately $5.6 million in Q2 2026 and basic and diluted EPS of -$0.08 per share.
• As of June 30, 2026, Microbot had cash and cash equivalents of approximately $3.15 million and short-term investments of about $64.2 million, with a strong current ratio of 18.56 and cash ratio of 17.33.
• Microbot expects to incur significant operating losses for the foreseeable future as it continues commercialization and research and development activities.
• The company depends heavily on the successful commercialization of the LIBERTY® system and faces risks related to manufacturing, regulatory approvals, market acceptance, reimbursement, and competition.
• Market acceptance depends on demonstrating safety, efficacy, cost-effectiveness, and gaining acceptance by medical professionals and payors.
• Microbot faces risks related to intellectual property protection, regulatory compliance, and the ability to raise additional capital to fund operations.
• The company operates internationally, including in Europe and Israel, and faces risks related to geopolitical conditions, currency fluctuations, and regulatory environments.
• Microbot has reported a greater than 100% growth in revenue and new customers for Q2 2026 compared to Q1 2026.
• The company reported Q1 and Q2 2026 losses and revenue below estimates in recent news coverage.
• Microbot began full U.S. launch of the LIBERTY system in April 2026.
• The company has received FDA clearance for the LIBERTY robotic system and holds patents expanding its market.
• Microbot has been covered by analysts with buy recommendations in late 2025 and early 2026.
• The company funds operations primarily through equity offerings and grants and has no committed external source of funds.
• Microbot incurs substantial costs associated with operating as a public company in the U.S.
• The company faces risks from potential delays in manufacturing scale-up, regulatory approvals, and market adoption.
• Microbot's financial figures and liquidity ratios are summarized from the latest SEC filings and provided for informational purposes only.